drugset
drugset / Trial / NCT01322451

Oral Bioavailability of Two Solid Formulations of GLPG0259.

NCT01322451 ↗

Phase 1 Completed 12 enrolled Lakefront Biotherapeutics NV
RandomizedCrossoverOpen-label

Summary

The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

Timeline

Start
2010-11
Primary completion
2010-12
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0259 Small molecule 50 mg Oral

Indications

No indication recorded.